» Articles » PMID: 21066863

[A Case of Allergic Bronchopulmonary Mycosis Caused by Schizophyllum Commune Presenting with Hyperattenuated Mucoid Impaction]

Overview
Specialty Pulmonary Medicine
Date 2010 Nov 12
PMID 21066863
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A 64-year-old woman was admitted to our hospital because of cough, bloody sputum and chest pain in January 2007. Chest computed tomography (CT) on admission revealed hyperattenuated mucoid impaction and consolidation in the right S3b. She was given a diagnosis of allergic bronchopulmonary mycosis caused by Schizophyllum commune. Treatment with 200 mg/day itraconazole and 15 mg/day oral prednisolone was begun, and her symptoms and consolidation resolved. In December 2007, consolidation in the left lower lobe appeared after itraconazole was stopped and replaced with oral prednisolone with inhaled fluticasone propionate. She again received 200 mg/day itraconazole and 15 mg/day oral prednisolone, resulting in a reduction in her consolidation. In May 2008, itraconazole was stopped and oral prednisolone was changed to inhaled salmeterol fluticasone propionate. In November 2008, her symptoms appeared again, and chest CT demonstrated hyperattenuated mucoid impaction and consolidation in the right S8. A transbronchial biopsy revealed granulomatosis, Charcot-Leyden crystals, and mucus infiltrated by eosinophils and fungi. Schizophyllum commune was isolated from her bronchial lavage fluid. A recurrence of allergic bronchopulmonary mycosis was diagnosed. Retreatment with itraconazole and oral prednisolone resulted in improvement of her symptoms and chest radiographic findings. To the best of our knowledge this is the first reported case of allergic bronchopulmonary mycosis caused by Schizophyllum commune presenting with hyperattenuated mucoid impaction.

Citing Articles

Allergic bronchopulmonary mycosis in with positive -specific IgE antibodies: A case report.

Takahashi H, Hamakawa M, Ishida T, Watanabe A Respirol Case Rep. 2024; 12(7):e01433.

PMID: 39015483 PMC: 11250149. DOI: 10.1002/rcr2.1433.


First report on cutaneous infectious granuloma caused by Schizophyllum commune.

Tian L, Mu Y, Zhang H, Su X, Yang C, Shu X BMC Infect Dis. 2018; 18(1):286.

PMID: 29940940 PMC: 6019233. DOI: 10.1186/s12879-018-3187-5.


Allergic Bronchopulmonary Mycosis Due to Schizophyllum commune Treated Effectively with Voriconazole.

Ishiguro T, Kagiyama N, Kojima A, Yamada M, Nakamoto Y, Takaku Y Intern Med. 2018; 57(17):2553-2557.

PMID: 29607966 PMC: 6172560. DOI: 10.2169/internalmedicine.0668-17.


A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune.

Kobayashi H, Taira T, Wakuda K, Takahashi T, Endo M Respir Med Case Rep. 2016; 19:54-7.

PMID: 27489762 PMC: 4961680. DOI: 10.1016/j.rmcr.2016.07.006.


Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses.

Chowdhary A, Kathuria S, Kumar Singh P, Agarwal K, Gaur S, Roy P Antimicrob Agents Chemother. 2013; 57(6):2845-8.

PMID: 23507274 PMC: 3716139. DOI: 10.1128/AAC.02619-12.